In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:BMRN), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 2 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.88, a high estimate of $110.00, and a low estimate of $85.00. This current average has decreased by 5.05% from the previous average price target of $106.25.
Exploring Analyst Ratings: An In-Depth Overview
ログインすると全部閲覧できます。
ログイン